Yellow fever vaccine protects mice against Zika virus infection

dc.creatorSantos, Ana C. Vicente
dc.creatorSilva, Francisca H. Guedes da
dc.creatorDumard, Carlos H.
dc.creatorFerreira, Vivian N. S.
dc.creatorCosta, Igor P. S. da
dc.creatorMachado, Ruana A.
dc.creatorAragão, Fernanda G. Q. Barros
dc.creatorNeris, Rômulo L. S.
dc.creatorSantos, Júlio S. dos
dc.creatorMiranda, Iranaia Assunção
dc.creatorFigueiredo, Claudia P.
dc.creatorDias, André A.
dc.creatorGomes, Andre M. O.
dc.creatorGuedes, Herbert L. de Matos
dc.creatorOliveira, Andrea C. Oliveira
dc.creatorSilva, Jerson L.
dc.date2021-12-09T13:14:06Z
dc.date2021-12-09T13:14:06Z
dc.date2021
dc.date.accessioned2023-09-26T20:41:19Z
dc.date.available2023-09-26T20:41:19Z
dc.identifierSANTOS, Ana C. Vicente et al. Yellow fever vaccine protects mice against Zika virus infection. PLoS Negl Trop Dis., v. 15, n. 11, e0009907, p. 1 - 18, Nov. 2021.
dc.identifier1935-2727
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/50234
dc.identifier10.1371/ journal.pntd.0009907
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8862037
dc.descriptionZika virus (ZIKV) emerged as an important infectious disease agent in Brazil in 2016. Infection usually leads to mild symptoms, but severe congenital neurological disorders and Guillain- Barre´ syndrome have been reported following ZIKV exposure. Creating an effective vaccine against ZIKV is a public health priority. We describe the protective effect of an already licensed attenuated yellow fever vaccine (YFV, 17DD) in type-I interferon receptor knockout mice (A129) and immunocompetent BALB/c and SV-129 (A129 background) mice infected with ZIKV. YFV vaccination provided protection against ZIKV, with decreased mortality in A129 mice, a reduction in the cerebral viral load in all mice, and weight loss prevention in BALB/c mice. The A129 mice that were challenged two and three weeks after the first dose of the vaccine were fully protected, whereas partial protection was observed five weeks after vaccination. In all cases, the YFV vaccine provoked a substantial decrease in the cerebral viral load. YFV immunization also prevented hippocampal synapse loss and microgliosis in ZIKV-infected mice. Our vaccine model is T cell-dependent, with AG129 mice being unable to tolerate immunization (vaccination is lethal in this mouse model), indicating the importance of IFN-γ in immunogenicity. To confirm the role of T cells, we immunized nude mice that we demonstrated to be very susceptible to infection. Immunization with YFV and challenge 7 days after booster did not protect nude mice in terms of weight loss and showed partial protection in the survival curve. When we evaluated the humoral response, the vaccine elicited significant antibody titers against ZIKV; however, it showed no neutralizing activity in vitro and in vivo. The data indicate that a cell-mediated response promotes protection against cerebral infection, which is crucial to vaccine protection, and it appears to not necessarily require a humoral response. This protective effect can also be attributed to innate factors, but more studies are needed to strengthen this hypothesis. Our findings open the way to using an available and inexpensive vaccine for large-scale immunization in the event of a ZIKV outbreak.
dc.formatapplication/pdf
dc.languageeng
dc.publisherPublic Library of Science
dc.rightsopen access
dc.subjectFebre amarela
dc.subjectVacina
dc.subjectInfecção por Vírus da Zika
dc.subjectProteção contra ratos
dc.subjectYellow fever
dc.subjectVaccine
dc.subjectAgainst
dc.subjectZika virus infection
dc.subjectProtects mice
dc.titleYellow fever vaccine protects mice against Zika virus infection
dc.typeArticle


Este ítem pertenece a la siguiente institución